SC
ALNY icon

Savant Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Savant Capital’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$263K Buy
878
+3
+0.3% +$905 ﹤0.01% 1592
2026
Q1 		$290K Hold
875
– – ﹤0.01% 1198
2025
Q4 		$348K Sell
875
-8
-0.9% -$3.54K ﹤0.01% 984
2025
Q3 		$403K Buy
+883
New +$360K ﹤0.01% 880
2025
Q1 		– Sell
-11,738
Closed -$2.76M – 1088
2024
Q4 		$2.76M Buy
11,738
+4,291
+58% +$1.13M 0.02% 356
2024
Q3 		$2.05M Buy
+7,447
New +$1.94M 0.02% 419

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Savant Capital's ALNY Position: Q2 2026 in Review

Savant Capital increased its Alnylam Pharmaceuticals (ALNY) stake by 0.34% in Q2 2026, buying an estimated $905 and bringing the position to 878 shares worth $263K. The position accounts for ﹤0.01% of the portfolio, ranked #1592.

Savant Capital first reported a position in ALNY in Q3 2024 and has held it in 6 quarters since. The position peaked at $2.76M in Q4 2024. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Savant Capital held 878 shares of Alnylam Pharmaceuticals worth $263K as of Q2 2026.
  • Savant Capital bought 3 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $905.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Savant Capital's portfolio in Q2 2026, its #1592 holding.
  • Savant Capital first reported a position in Alnylam Pharmaceuticals in Q3 2024 and has held it in 6 quarters since.
  • Savant Capital's Alnylam Pharmaceuticals position peaked at $2.76M in Q4 2024.
  • 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Savant Capital's 13F filing for Q2 2026, filed 10 Aug 2026.